Long-term follow-up of Lambert-Eaton syndrome treated with intravenous immunoglobulin

Muscle and Nerve

Volumn 20, Issue 6, 1997, Pages 674-678

  Muchnik, Salomon ^a   Losavio, Adriana S ^a   Vidal, Alfredo ^a   Cura, Leila ^a   Mazia, Claudio ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

high dose intravenous immunoglobulin; Lambert Eaton myasthenic syndrome; long term treatment

Indexed keywords

IMMUNOGLOBULIN G;

ADULT; ARTICLE; CASE REPORT; DRUG EFFICACY; DRUG MEGADOSE; EATON LAMBERT SYNDROME; FEMALE; FOLLOW UP; HUMAN; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; LEG MUSCLE; LONG TERM CARE; MUSCLE STRENGTH; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL;

ADULT; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; LAMBERT-EATON MYASTHENIC SYNDROME; TIME FACTORS;

EID: 0030945792     PISSN: 0148639X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4598(199706)20:6<674::AID-MUS3>3.0.CO;2-5     Document Type: Article

References (16)

1. Bain P, Elrington G, Goodger E, Misbah S, Panejires P, McPherson K, Chapel H, Newsom-Davis J: A randomised double blind controlled study of intravenous immunoglobulin in the Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 1994;57:1287.
2. Bird J: Clinical and electrophysiologic improvement in Lambert-Eaton syndrome with intravenous immunoglobulin therapy Neurology 1992;42:1422-1423.
3. Drachman DB, McIntosh KR, Reim J, Balcer L: Strategies for treatment of myasthenia gravis. Ann NY Acad Sci 1993;681: 515-525.
4. Dweyer JM: Manipulating the immune system with immune globulin. N Engl J Med 1992;326:107-116.
5. Edan G, Landgraf F: Experience with intravenous immunoglobulin in myasthenia gravis: a review. J Neurol Neurosurg Psychiatry 1994;57(suppl):55-56.
6. Engel AG: Changes in end-plate structure in neuromuscular transmission disorders, in Liss AR (ed): The Vertebrate Neuromuscular Junction. New York, 1987, pp 415-428.
7. Engel AG, Fukunaga H, Osame M: Stereometric estimation of the area of the freeze-fractured membrane. Muscle Nerve 1982;5:682-685.
8. Ferrero B, Durelli L, Cavallo R, Dutto A, Aimo G, Pecchio F, Bergamasco B: Therapies for exacerbation of myasthenia gravis. The mechanism of action of intravenous high-dose immunoglobulin G. Ann NY Acad Sci 1993;681:563-566.
9. Fukunaga H, Engel AG, Lang B, Newsom-Davis J, Vincent A: Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones. Proc Natl Acad Sci USA 1983;80:7636-7640.
10. Fukunaga H, Engel AG, Osame M, Lambert EH: Paucity and disorganization of presynaptic membrane active zones in the Lambert-Eaton myasthenic syndrome. Muscle Nerve 1982;5: 686-697.
11. Fukuoka T, Engel AG, Lang B, Newsom-Davis J, Prior C, Wray DW: Lambert-Eaton myasthenic syndrome: I. Early morphological effects of IgG on the presynaptic membrane active zones. Ann Neurol 1987;22:193-199.
12. Fukuoka T, Engel AG, Lang B, Newsom-Davis J, Vincent A: Lambert-Eaton myasthenic syndrome: II. Immunoelectron microscopy localization of IgG at the mouse motor end-plate. Ann Neurol 1987;22:200-211.
13. Jablecki CK: Electrodiagnostic evaluation of patients with myasthenia gravis and related disorders. Neurol Clin 1985;3: 557-571.
14. Jablecki CK: AAEE case report 3: Myasthenia gravis. Muscle Nerve 1991;14:391-397.
15. Keesey JC: Electrodiagnostic approach to defects of neuromuscular transmission. Muscle Nerve 1989;12:613-626.
16. Lambert ET, Elmqvist D: Quantal components of end plate potentials in the myasthenic syndrome. Ann NY Acad Sci 1971;183:183-199.